GSK sells liver disease drug candidate to Alfasigma for $690m
Posted:
Italy-based Alfasigma will acquire worldwide development, manufacturing, and commercialisation duties for linerixibat, GSK’s ileal bile acid transporter (IBAT) inhibitor being developed for cholestatic pruritus in primary biliary cholangitis (PBC).
Based on research completed as part of a multi-year collaboration with Nokia Bell Labs, biomedical engineers at Duke University are developing a solution. Using a custom-built optical coherence tomography (OCT) imaging system together with artificial intelligence (AI) models grounded in…
Rare conditions in the ICU include both formally classified rare diseases and conditions that occur infrequently in critical care settings. These patients often face delayed diagnosis, limited specialist expertise and complex multisystem involvement, all of which contribute to poorer outcomes…
Attendees
Sponsors and Exhibitors
Contact us